阿波贝克
生物
胞苷脱氨酶
突变
遗传学
突变
胞嘧啶脱氨酶
胞苷
癌症研究
基因组
基因
生物化学
遗传增强
酶
作者
Steven A. Roberts,Michael S. Lawrence,Leszek J. Klimczak,Sara A. Grimm,David C. Fargo,Petar Stojanov,Adam Kieżun,Gregory V. Kryukov,Scott L. Carter,Gordon Saksena,Shawn Harris,Ruchir Shah,Michael A. Resnick,Gad Getz,Dmitry A. Gordenin
出处
期刊:Nature Genetics
[Springer Nature]
日期:2013-07-14
卷期号:45 (9): 970-976
被引量:989
摘要
Recent studies indicate that a subclass of APOBEC cytidine deaminases, which convert cytosine to uracil during RNA editing and retrovirus or retrotransposon restriction, may induce mutation clusters in human tumors. We show here that throughout cancer genomes APOBEC-mediated mutagenesis is pervasive and correlates with APOBEC mRNA levels. Mutation clusters in whole-genome and exome data sets conformed to the stringent criteria indicative of an APOBEC mutation pattern. Applying these criteria to 954,247 mutations in 2,680 exomes from 14 cancer types, mostly from The Cancer Genome Atlas (TCGA), showed a significant presence of the APOBEC mutation pattern in bladder, cervical, breast, head and neck, and lung cancers, reaching 68% of all mutations in some samples. Within breast cancer, the HER2-enriched subtype was clearly enriched for tumors with the APOBEC mutation pattern, suggesting that this type of mutagenesis is functionally linked with cancer development. The APOBEC mutation pattern also extended to cancer-associated genes, implying that ubiquitous APOBEC-mediated mutagenesis is carcinogenic.
科研通智能强力驱动
Strongly Powered by AbleSci AI